Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome

Eur J Clin Invest 2012; 42 (4): 411–418 Background  Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will develop NAFLD and not all patients with NAFLD have the MS. We sought to investigate the differences bet...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical investigation Vol. 42; no. 4; pp. 411 - 418
Main Authors: Yilmaz, Yusuf, Senates, Ebubekir, Ayyildiz, Talat, Colak, Yasar, Tuncer, Ilyas, Ovunc, Ayse Oya Kurdas, Dolar, Enver, Kalayci, Cem
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Publishing Ltd 01-04-2012
Wiley-Blackwell
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Eur J Clin Invest 2012; 42 (4): 411–418 Background  Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will develop NAFLD and not all patients with NAFLD have the MS. We sought to investigate the differences between patients with biopsy‐proven NAFLD with and without the MS. Methods  A total of 357 consecutive patients with biopsy‐proven NAFLD were analysed. Of them, 216 patients had nonalcoholic steatohepatitis (NASH) and 96 a fibrosis score ≥ 2. The MS was defined as ≥ 3 of the ATP III criteria. Results  A total of 214 patients with NAFLD met the criteria for the MS, while the remaining 143 did not. In NAFLD patients with the MS, homeostasis model of insulin resistance (P = 0·03; OR, 1·06; 95% CI, 1·023–1·25 per unit increase) and diabetes (P = 0·01; OR, 1·2; 95% CI, 1·1–2·4) were independent predictors of NASH. In NAFLD patients without the MS, the only variable independently associated with NASH was haemoglobin (P = 0·007; OR, 1·9; 95% CI, 1·4–3·6 per 50 g/L increase). Alanine aminotransferase (P = 0·03; OR, 1·04; 95% CI, 1·006–1·11 per 10 U/L increase) was an independent predictor of fibrosis ≥ 2 in NAFLD patients with the MS, while haemoglobin (P = 0·02; OR, 1·4; 95% CI, 1·2–1·9 per 50 g/L increase) was the only variable significantly associated with fibrosis ≥ 2 in NAFLD patients without the MS. Conclusions  Increased haemoglobin in NAFLD subjects without MS should be considered in the selection of cases for histological assessment.
AbstractList Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will develop NAFLD and not all patients with NAFLD have the MS. We sought to investigate the differences between patients with biopsy-proven NAFLD with and without the MS. A total of 357 consecutive patients with biopsy-proven NAFLD were analysed. Of them, 216 patients had nonalcoholic steatohepatitis (NASH) and 96 a fibrosis score ≥ 2. The MS was defined as ≥ 3 of the ATP III criteria. A total of 214 patients with NAFLD met the criteria for the MS, while the remaining 143 did not. In NAFLD patients with the MS, homeostasis model of insulin resistance (P = 0·03; OR, 1·06; 95% CI, 1·023-1·25 per unit increase) and diabetes (P = 0·01; OR, 1·2; 95% CI, 1·1-2·4) were independent predictors of NASH. In NAFLD patients without the MS, the only variable independently associated with NASH was haemoglobin (P = 0·007; OR, 1·9; 95% CI, 1·4-3·6 per 50 g/L increase). Alanine aminotransferase (P = 0·03; OR, 1·04; 95% CI, 1·006-1·11 per 10 U/L increase) was an independent predictor of fibrosis ≥ 2 in NAFLD patients with the MS, while haemoglobin (P = 0·02; OR, 1·4; 95% CI, 1·2-1·9 per 50 g/L increase) was the only variable significantly associated with fibrosis ≥ 2 in NAFLD patients without the MS. Increased haemoglobin in NAFLD subjects without MS should be considered in the selection of cases for histological assessment.
BACKGROUNDNonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will develop NAFLD and not all patients with NAFLD have the MS. We sought to investigate the differences between patients with biopsy-proven NAFLD with and without the MS.METHODSA total of 357 consecutive patients with biopsy-proven NAFLD were analysed. Of them, 216 patients had nonalcoholic steatohepatitis (NASH) and 96 a fibrosis score ≥ 2. The MS was defined as ≥ 3 of the ATP III criteria.RESULTSA total of 214 patients with NAFLD met the criteria for the MS, while the remaining 143 did not. In NAFLD patients with the MS, homeostasis model of insulin resistance (P = 0·03; OR, 1·06; 95% CI, 1·023-1·25 per unit increase) and diabetes (P = 0·01; OR, 1·2; 95% CI, 1·1-2·4) were independent predictors of NASH. In NAFLD patients without the MS, the only variable independently associated with NASH was haemoglobin (P = 0·007; OR, 1·9; 95% CI, 1·4-3·6 per 50 g/L increase). Alanine aminotransferase (P = 0·03; OR, 1·04; 95% CI, 1·006-1·11 per 10 U/L increase) was an independent predictor of fibrosis ≥ 2 in NAFLD patients with the MS, while haemoglobin (P = 0·02; OR, 1·4; 95% CI, 1·2-1·9 per 50 g/L increase) was the only variable significantly associated with fibrosis ≥ 2 in NAFLD patients without the MS.CONCLUSIONSIncreased haemoglobin in NAFLD subjects without MS should be considered in the selection of cases for histological assessment.
Eur J Clin Invest 2012; 42 (4): 411–418 Background  Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will develop NAFLD and not all patients with NAFLD have the MS. We sought to investigate the differences between patients with biopsy‐proven NAFLD with and without the MS. Methods  A total of 357 consecutive patients with biopsy‐proven NAFLD were analysed. Of them, 216 patients had nonalcoholic steatohepatitis (NASH) and 96 a fibrosis score ≥ 2. The MS was defined as ≥ 3 of the ATP III criteria. Results  A total of 214 patients with NAFLD met the criteria for the MS, while the remaining 143 did not. In NAFLD patients with the MS, homeostasis model of insulin resistance (P = 0·03; OR, 1·06; 95% CI, 1·023–1·25 per unit increase) and diabetes (P = 0·01; OR, 1·2; 95% CI, 1·1–2·4) were independent predictors of NASH. In NAFLD patients without the MS, the only variable independently associated with NASH was haemoglobin (P = 0·007; OR, 1·9; 95% CI, 1·4–3·6 per 50 g/L increase). Alanine aminotransferase (P = 0·03; OR, 1·04; 95% CI, 1·006–1·11 per 10 U/L increase) was an independent predictor of fibrosis ≥ 2 in NAFLD patients with the MS, while haemoglobin (P = 0·02; OR, 1·4; 95% CI, 1·2–1·9 per 50 g/L increase) was the only variable significantly associated with fibrosis ≥ 2 in NAFLD patients without the MS. Conclusions  Increased haemoglobin in NAFLD subjects without MS should be considered in the selection of cases for histological assessment.
Author Ayyildiz, Talat
Dolar, Enver
Senates, Ebubekir
Tuncer, Ilyas
Yilmaz, Yusuf
Ovunc, Ayse Oya Kurdas
Colak, Yasar
Kalayci, Cem
Author_xml – sequence: 1
  givenname: Yusuf
  surname: Yilmaz
  fullname: Yilmaz, Yusuf
  organization: Department of Gastroenterology, Marmara University, School of Medicine, Pendik, Istanbul, Turkey
– sequence: 2
  givenname: Ebubekir
  surname: Senates
  fullname: Senates, Ebubekir
  organization: Department of Gastroenterology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey
– sequence: 3
  givenname: Talat
  surname: Ayyildiz
  fullname: Ayyildiz, Talat
  organization: Department of Gastroenterology, Uludag University Medical School, Bursa, Turkey
– sequence: 4
  givenname: Yasar
  surname: Colak
  fullname: Colak, Yasar
  organization: Department of Gastroenterology, Goztepe Education and Research Hospital, Istanbul, Turkey
– sequence: 5
  givenname: Ilyas
  surname: Tuncer
  fullname: Tuncer, Ilyas
  organization: Department of Gastroenterology, Goztepe Education and Research Hospital, Istanbul, Turkey
– sequence: 6
  givenname: Ayse Oya Kurdas
  surname: Ovunc
  fullname: Ovunc, Ayse Oya Kurdas
  organization: Department of Gastroenterology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey
– sequence: 7
  givenname: Enver
  surname: Dolar
  fullname: Dolar, Enver
  organization: Department of Gastroenterology, Uludag University Medical School, Bursa, Turkey
– sequence: 8
  givenname: Cem
  surname: Kalayci
  fullname: Kalayci, Cem
  organization: Department of Gastroenterology, Marmara University, School of Medicine, Pendik, Istanbul, Turkey
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25589721$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21913918$$D View this record in MEDLINE/PubMed
BookMark eNqNkU1v1DAQhi1URLeFv4B8QZwS_BEn9oED2palUvk4FIG4WBPH1npJ4mJ7YZdfT9Jdliu-2NI8r2f0zAU6G8NoEcKUlHQ6rzYl5bUoGK9ZyQilJWFCNeXuEVqcCmdoQQitCqYado4uUtoQQiTl7Ak6Z1RRrqhcoK_LNUQw2Ub_G7IPIw4OT92gN2Edem-wg5z3uPc_bcSdTxaSxdsx2h6y7XAOOK8tHmyG9gFP-7GLYbBP0WMHfbLPjvcl-vz2-m75rrj9uLpZvrktTMXrpqC1qWUjW6Zc1SnWMkels0JWdSOZMhQMM4zUIDgIB6C4IoI6Z0nXgms7zi_Ry8O_9zH82NqU9eCTsX0Pow3bpBWTishKiomUB9LEkFK0Tt9HP0Dca0r0rFVv9GxPz_b0rFU_aNW7Kfr82GTbDrY7Bf96nIAXRwCSgd5FGI1P_zgh5LQGOnGvD9wv39v9fw-gr5c382vKF4e8T9nuTnmI33Xd8EboLx9WelVfvf8kv93pK_4H7culRg
CitedBy_id crossref_primary_10_3390_ijms17030281
crossref_primary_10_1097_MEG_0000000000000434
crossref_primary_10_12677_ACM_2022_121050
crossref_primary_10_3390_ijerph17061818
crossref_primary_10_3748_wjg_v20_i39_14219
crossref_primary_10_1089_met_2012_0147
crossref_primary_10_1159_000438473
crossref_primary_10_3109_00365521_2014_983160
crossref_primary_10_1111_apt_12255
crossref_primary_10_1097_MEG_0000000000000342
crossref_primary_10_1155_2013_124958
crossref_primary_10_14218_JCTH_2016_00068
crossref_primary_10_29058_mjwbs_811398
crossref_primary_10_5009_gnl_2014_8_3_313
crossref_primary_10_1097_MEG_0000000000000409
crossref_primary_10_1016_j_dld_2016_10_004
crossref_primary_10_3109_00365521_2014_958099
crossref_primary_10_3390_ijms19071977
crossref_primary_10_4254_wjh_v4_i12_332
crossref_primary_10_1016_j_cca_2012_04_019
crossref_primary_10_1371_journal_pone_0171502
crossref_primary_10_1186_s12872_021_02060_z
crossref_primary_10_1038_s41598_018_31845_0
crossref_primary_10_1097_MEG_0000000000000254
crossref_primary_10_1016_j_diabres_2018_08_011
crossref_primary_10_1097_MEG_0000000000000255
crossref_primary_10_1017_S1368980015002293
Cites_doi 10.2174/138161210791208875
10.1055/s-2001-12927
10.1111/j.1365-2362.2009.02234.x
10.1038/ncpendmet0505
10.1161/01.CIR.0000111245.75752.C6
10.1161/CIRCULATIONAHA.105.169404
10.1016/j.mcna.2007.06.001
10.1002/pmic.200300495
10.1016/S0140-6736(05)67402-8
10.1111/j.1751-2980.2008.00331.x
10.1002/hep.20466
10.1074/jbc.M702163200
10.1161/ATVBAHA.107.147538
10.1136/gut.2009.186668
10.1042/CS20070402
10.1053/jhep.2003.50161
10.1017/S0029665110000030
10.1089/152308601300185250
10.1136/gut.2007.140087
10.1002/hep.22622
10.1016/j.dld.2010.01.016
10.1042/BJ20071570
10.1111/j.1572-0241.1999.01377.x
10.1053/jhep.2003.50325
10.1002/hep.20701
10.1053/jhep.2003.50193
10.1007/s11894-008-0012-0
10.1111/j.1365-2613.2008.00590.x
10.3949/ccjm.75.10.721
10.1016/j.annepidem.2007.05.013
10.1161/01.CIR.0000133317.49796.0E
10.3109/03630260903346676
ContentType Journal Article
Copyright 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation
2015 INIST-CNRS
2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.
Copyright_xml – notice: 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation
– notice: 2015 INIST-CNRS
– notice: 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1111/j.1365-2362.2011.02597.x
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2362
EndPage 418
ExternalDocumentID 10_1111_j_1365_2362_2011_02597_x
21913918
25589721
ECI2597
ark_67375_WNG_G6DMP8ZT_D
Genre article
Journal Article
GroupedDBID ---
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29G
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
DUUFO
EAD
EAP
EAS
EBB
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EPT
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YFH
ZGI
ZXP
ZZTAW
~IA
~WT
08R
AAPBV
AAUGY
AAVGM
ABHUG
ABPTK
ACXME
ADAWD
ADDAD
AFVGU
AGJLS
AKALU
IQODW
ZA5
CGR
CUY
CVF
ECM
EIF
NPM
AAMNL
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c4367-16c6878b29f4d92b2f18fe58467829c1ac2c206a53a5faa939051ffe0dbafbd33
IEDL.DBID 33P
ISSN 0014-2972
IngestDate Sat Aug 17 02:50:35 EDT 2024
Thu Nov 21 23:09:27 EST 2024
Sat Sep 28 08:01:07 EDT 2024
Sun Oct 22 16:05:34 EDT 2023
Sat Aug 24 01:15:17 EDT 2024
Wed Oct 30 09:53:40 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Endocrinopathy
Pancreatic hormone
Digestive system
Unrelated donor
Liver
Metabolic diseases
Cardiovascular disease
Hepatic disease
Metabolic syndrome
Insulin
Steatosis
Characterization
Medicine
nonalcoholic steatohepatitis
Target tissue resistance
haemoglobin
Non alcoholic steatohepatitis
Fibrosis
Hemoglobin
Digestive diseases
Insulin resistance
Language English
License CC BY 4.0
2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4367-16c6878b29f4d92b2f18fe58467829c1ac2c206a53a5faa939051ffe0dbafbd33
Notes ArticleID:ECI2597
istex:47CADE98ECBD9DCCCF4121E650EA0554510AC07B
ark:/67375/WNG-G6DMP8ZT-D
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 21913918
PQID 928908485
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_928908485
crossref_primary_10_1111_j_1365_2362_2011_02597_x
pubmed_primary_21913918
pascalfrancis_primary_25589721
wiley_primary_10_1111_j_1365_2362_2011_02597_x_ECI2597
istex_primary_ark_67375_WNG_G6DMP8ZT_D
PublicationCentury 2000
PublicationDate April 2012
PublicationDateYYYYMMDD 2012-04-01
PublicationDate_xml – month: 04
  year: 2012
  text: April 2012
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: Oxford
– name: England
PublicationTitle European journal of clinical investigation
PublicationTitleAlternate Eur J Clin Invest
PublicationYear 2012
Publisher Blackwell Publishing Ltd
Wiley-Blackwell
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley-Blackwell
References Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010;16:1941-51.
Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:27-38.
Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008;48:2086-7.
Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010;42: 32030.
Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
Xu L, Xu CF, Yu CH, Miao M, Li YM. Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study. Gut 2009;58:1706-7.
Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, Smith C et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004;4:244-56.
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
Alayash AI, Patel RP, Cashon RE. Redox reactions of hemoglobin and myoglobin: biological and toxicological implications. Antioxid Redox Signal 2001;3:313-27.
Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab 2007;3:458-69.
Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.
Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J 2008;411:1-18.
Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007;17:863-9.
Duvnjak L, Duvnjak M. The metabolic syndrome - an ongoing story. J Physiol Pharmacol 2009;60(Suppl. 7):19-24.
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, Ge H et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. J Biol Chem 2007;282:23698-707.
Leung TM, Tipoe GL, Liong EC, Lau TY, Fung ML, Nanji AA. Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis. Int J Exp Pathol 2008;89:241-50.
Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin 2009;33:S46-57.
Zeng MD, Fan JG, Lu LG, Li YM, Chen CW, Wang BY et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis 2008;9:108-12.
Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep 2008;10:73-80.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-52.
Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008;115:141-50.
Trak-Smayra V, Dargere D, Noun R, Albuquerque M, Yaghi C, Gannagé-Yared MH et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 2009;58:825-32.
Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007;91:1125-49.
Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008;75:721-8.
Alberti KG, Zimmet P, Shaw J; for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-62.
Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010;69:211-20.
Pearson TC. Hemorheology in the erythrocytoses. Mt Sinai J Med 2001;68:182-91.
Green RM. NASH - hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003;38:14-7.
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
2007; 17
2010; 16
2004; 40
2007; 282
2005; 112
2009; 60
2008; 9
2004; 4
2005; 41
2003; 37
2007; 91
2003; 38
2008; 10
2008; 75
2004; 109
2001; 68
2010; 40
2001; 21
2009; 33
2004; 110
2009; 58
2010; 42
2010; 69
2005; 366
2008; 28
2008; 48
2008; 89
2001; 3
2008; 115
2008; 411
2007; 3
1999; 94
e_1_2_8_27_2
e_1_2_8_28_2
e_1_2_8_29_2
e_1_2_8_23_2
e_1_2_8_24_2
e_1_2_8_25_2
e_1_2_8_26_2
e_1_2_8_9_2
e_1_2_8_2_2
Pearson TC (e_1_2_8_30_2) 2001; 68
e_1_2_8_4_2
e_1_2_8_3_2
e_1_2_8_6_2
e_1_2_8_5_2
e_1_2_8_8_2
e_1_2_8_7_2
e_1_2_8_20_2
e_1_2_8_21_2
e_1_2_8_22_2
e_1_2_8_16_2
Duvnjak L (e_1_2_8_11_2) 2009; 60
e_1_2_8_17_2
e_1_2_8_18_2
e_1_2_8_19_2
e_1_2_8_12_2
e_1_2_8_35_2
e_1_2_8_13_2
e_1_2_8_34_2
e_1_2_8_14_2
e_1_2_8_15_2
e_1_2_8_31_2
e_1_2_8_10_2
e_1_2_8_33_2
e_1_2_8_32_2
References_xml – volume: 115
  start-page: 141
  year: 2008
  end-page: 50
  article-title: Non‐alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations
  publication-title: Clin Sci (Lond)
– volume: 33
  start-page: S46
  year: 2009
  end-page: 57
  article-title: Iron overload: consequences, assessment, and monitoring
  publication-title: Hemoglobin
– volume: 16
  start-page: 1941
  year: 2010
  end-page: 51
  article-title: Insulin resistance in nonalcoholic fatty liver disease
  publication-title: Curr Pharm Des
– volume: 37
  start-page: 917
  year: 2003
  end-page: 23
  article-title: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
  publication-title: Hepatology
– volume: 3
  start-page: 458
  year: 2007
  end-page: 69
  article-title: Nonalcoholic fatty liver disease: from pathogenesis to patient care
  publication-title: Nat Clin Pract Endocrinol Metab
– volume: 48
  start-page: 2086
  year: 2008
  end-page: 7
  article-title: Is biopsy always necessary? Toward a clinico‐laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity
  publication-title: Hepatology
– volume: 112
  start-page: 2735
  year: 2005
  end-page: 52
  article-title: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement
  publication-title: Circulation
– volume: 89
  start-page: 241
  year: 2008
  end-page: 50
  article-title: Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis
  publication-title: Int J Exp Pathol
– volume: 37
  start-page: 1202
  year: 2003
  end-page: 19
  article-title: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference
  publication-title: Hepatology
– volume: 40
  start-page: 1387
  year: 2004
  end-page: 95
  article-title: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity
  publication-title: Hepatology
– volume: 40
  start-page: 35
  year: 2010
  end-page: 53
  article-title: A catalogue of reporting guidelines for health research
  publication-title: Eur J Clin Invest
– volume: 282
  start-page: 23698
  year: 2007
  end-page: 707
  article-title: Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis
  publication-title: J Biol Chem
– volume: 10
  start-page: 73
  year: 2008
  end-page: 80
  article-title: Nonalcoholic fatty liver disease as a component of the metabolic syndrome
  publication-title: Curr Gastroenterol Rep
– volume: 9
  start-page: 108
  year: 2008
  end-page: 12
  article-title: Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases
  publication-title: J Dig Dis
– volume: 41
  start-page: 1313
  year: 2005
  end-page: 21
  article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease
  publication-title: Hepatology
– volume: 94
  start-page: 2467
  year: 1999
  end-page: 74
  article-title: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
  publication-title: Am J Gastroenterol
– volume: 411
  start-page: 1
  year: 2008
  end-page: 18
  article-title: Liver fibrosis
  publication-title: Biochem J
– volume: 42
  year: 2010
  article-title: From the metabolic syndrome to NAFLD or vice versa?
  publication-title: Dig Liver Dis
– volume: 109
  start-page: 433
  year: 2004
  end-page: 8
  article-title: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition
  publication-title: Circulation
– volume: 38
  start-page: 14
  year: 2003
  end-page: 7
  article-title: NASH – hepatic metabolism and not simply the metabolic syndrome
  publication-title: Hepatology
– volume: 68
  start-page: 182
  year: 2001
  end-page: 91
  article-title: Hemorheology in the erythrocytoses
  publication-title: Mt Sinai J Med
– volume: 366
  start-page: 1059
  year: 2005
  end-page: 62
  article-title: The metabolic syndrome: a new worldwide definition
  publication-title: Lancet
– volume: 58
  start-page: 825
  year: 2009
  end-page: 32
  article-title: Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery
  publication-title: Gut
– volume: 110
  start-page: 227
  year: 2004
  end-page: 39
  article-title: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
  publication-title: Circulation
– volume: 91
  start-page: 1125
  year: 2007
  end-page: 49
  article-title: Nonalcoholic fatty liver disease as a complication of insulin resistance
  publication-title: Med Clin North Am
– volume: 58
  start-page: 1706
  year: 2009
  end-page: 7
  article-title: Haemoglobin and non‐alcoholic fatty liver disease: further evidence from a population‐based study
  publication-title: Gut
– volume: 75
  start-page: 721
  year: 2008
  end-page: 8
  article-title: Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome
  publication-title: Cleve Clin J Med
– volume: 21
  start-page: 27
  year: 2001
  end-page: 41
  article-title: Etiopathogenesis of nonalcoholic steatohepatitis
  publication-title: Semin Liver Dis
– volume: 28
  start-page: 27
  year: 2008
  end-page: 38
  article-title: Fatty liver: a novel component of the metabolic syndrome
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 60
  start-page: 19
  issue: Suppl. 7
  year: 2009
  end-page: 24
  article-title: The metabolic syndrome – an ongoing story
  publication-title: J Physiol Pharmacol
– volume: 3
  start-page: 313
  year: 2001
  end-page: 27
  article-title: Redox reactions of hemoglobin and myoglobin: biological and toxicological implications
  publication-title: Antioxid Redox Signal
– volume: 69
  start-page: 211
  year: 2010
  end-page: 20
  article-title: Non‐alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome
  publication-title: Proc Nutr Soc
– volume: 17
  start-page: 863
  year: 2007
  end-page: 9
  article-title: Nonalcoholic fatty liver disease
  publication-title: Ann Epidemiol
– volume: 4
  start-page: 244
  year: 2004
  end-page: 56
  article-title: Mining biomarkers in human sera using proteomic tools
  publication-title: Proteomics
– ident: e_1_2_8_7_2
  doi: 10.2174/138161210791208875
– ident: e_1_2_8_15_2
  doi: 10.1055/s-2001-12927
– ident: e_1_2_8_18_2
  doi: 10.1111/j.1365-2362.2009.02234.x
– ident: e_1_2_8_9_2
  doi: 10.1038/ncpendmet0505
– ident: e_1_2_8_12_2
  doi: 10.1161/01.CIR.0000111245.75752.C6
– ident: e_1_2_8_34_2
  doi: 10.1161/CIRCULATIONAHA.105.169404
– ident: e_1_2_8_8_2
  doi: 10.1016/j.mcna.2007.06.001
– ident: e_1_2_8_28_2
  doi: 10.1002/pmic.200300495
– volume: 60
  start-page: 19
  issue: 7
  year: 2009
  ident: e_1_2_8_11_2
  article-title: The metabolic syndrome – an ongoing story
  publication-title: J Physiol Pharmacol
  contributor:
    fullname: Duvnjak L
– ident: e_1_2_8_35_2
  doi: 10.1016/S0140-6736(05)67402-8
– ident: e_1_2_8_19_2
  doi: 10.1111/j.1751-2980.2008.00331.x
– ident: e_1_2_8_2_2
  doi: 10.1002/hep.20466
– ident: e_1_2_8_29_2
  doi: 10.1074/jbc.M702163200
– ident: e_1_2_8_6_2
  doi: 10.1161/ATVBAHA.107.147538
– ident: e_1_2_8_26_2
  doi: 10.1136/gut.2009.186668
– volume: 68
  start-page: 182
  year: 2001
  ident: e_1_2_8_30_2
  article-title: Hemorheology in the erythrocytoses
  publication-title: Mt Sinai J Med
  contributor:
    fullname: Pearson TC
– ident: e_1_2_8_4_2
  doi: 10.1042/CS20070402
– ident: e_1_2_8_22_2
  doi: 10.1053/jhep.2003.50161
– ident: e_1_2_8_5_2
  doi: 10.1017/S0029665110000030
– ident: e_1_2_8_27_2
  doi: 10.1089/152308601300185250
– ident: e_1_2_8_25_2
  doi: 10.1136/gut.2007.140087
– ident: e_1_2_8_33_2
  doi: 10.1002/hep.22622
– ident: e_1_2_8_16_2
  doi: 10.1016/j.dld.2010.01.016
– ident: e_1_2_8_24_2
  doi: 10.1042/BJ20071570
– ident: e_1_2_8_20_2
  doi: 10.1111/j.1572-0241.1999.01377.x
– ident: e_1_2_8_17_2
  doi: 10.1053/jhep.2003.50325
– ident: e_1_2_8_21_2
  doi: 10.1002/hep.20701
– ident: e_1_2_8_3_2
  doi: 10.1053/jhep.2003.50193
– ident: e_1_2_8_14_2
  doi: 10.1007/s11894-008-0012-0
– ident: e_1_2_8_31_2
  doi: 10.1111/j.1365-2613.2008.00590.x
– ident: e_1_2_8_13_2
  doi: 10.3949/ccjm.75.10.721
– ident: e_1_2_8_10_2
  doi: 10.1016/j.annepidem.2007.05.013
– ident: e_1_2_8_23_2
  doi: 10.1161/01.CIR.0000133317.49796.0E
– ident: e_1_2_8_32_2
  doi: 10.3109/03630260903346676
SSID ssj0008132
Score 2.2504466
Snippet Eur J Clin Invest 2012; 42 (4): 411–418 Background  Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS)....
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will develop NAFLD...
BACKGROUNDNonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will...
SourceID proquest
crossref
pubmed
pascalfrancis
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 411
SubjectTerms Adult
Age Factors
Biological and medical sciences
Biomarkers - metabolism
Biopsy
Cross-Sectional Studies
Fatty Liver - blood
Fatty Liver - diagnosis
Fatty Liver - physiopathology
Female
Fibrosis
Gastroenterology. Liver. Pancreas. Abdomen
General aspects
haemoglobin
Hemoglobins - metabolism
Humans
insulin resistance
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Logistic Models
Male
Medical sciences
Metabolic diseases
Metabolic Syndrome - blood
Metabolic Syndrome - diagnosis
Metabolic Syndrome - physiopathology
Middle Aged
Miscellaneous
Non-alcoholic Fatty Liver Disease
nonalcoholic steatohepatitis
Other diseases. Semiology
Other metabolic disorders
ROC Curve
Severity of Illness Index
Sex Factors
Turkey
Title Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome
URI https://api.istex.fr/ark:/67375/WNG-G6DMP8ZT-D/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2362.2011.02597.x
https://www.ncbi.nlm.nih.gov/pubmed/21913918
https://search.proquest.com/docview/928908485
Volume 42
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB6aFEIuTZtH66YJOpTeXFYP2_Kx7G4ehYRAExp6EbIeUJrsll0vpP--GsnrZEsOoeRmhMfYM5rRJ8_MJ4CP8ZSjgENz1miXC-tc3hhW5VZS4worRKJrOvlWnV_L0Rhpcr4ue2ESP0T_ww09I8ZrdHDdzFedPFZohQjcMXEGJF99RjwZNg2xm4Nf9EFZUp6Iw6nIWV39U9Tz6INWVqqXqPQ7rJzU86A8n069eAyWrqLcuEwdbT3nB76GVx1YJV_S7HoDL9xkGzbOunT8DlwPe7rn1M1Jpp5MENvHc3d_GuJ12_4hN1j8QbpcEFlMYgONs6SdkoA_ya1rw1TE25f8CbtwdTS-HJ7k3VENuRE8hFpamlJWsmG1F7ZmDfNUehfBjWS1odowwwalLrguvNY1R1ow793ANto3lvM9WA-v594B4Za7qqLaO8dFKeomIKCyHEhnTRHGbQZ0aRb1OzFyqAc7maAyhSpTqDIVVabuMvgU7dcL6NkvrGirCvX9_Fgdl6OzC_njUo0yOFwxcC8Qdl4SiY4yIEuLq-CImF3REzddzFWNKVspZJHB2zQT7oUpkq9SmUEZDf7k91bj4Slevf9fwX3YDMMslRp9gPV2tnAHsDa3i8PoH38BfCgLqg
link.rule.ids 315,782,786,1408,27933,27934,46064,46488
linkProvider Wiley-Blackwell
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LTxsxEB5RkNpeWvqg3baAD1VvW8X2PrxHlASCIBFSUxX1Ynn9kBBtUpGNRP89HnuzNBUHhLitVp6Vd8Yz_myPvwH4HKoceRyaslrZNDPWprVmZWoE1TY3WRbpmkbfysm5GAyRJudkdRcm8kN0G27oGSFeo4PjhvS6l4cULR-CWypOD-XLrx5QbmWFH5d4n4OfdWFZUB6pw2mWsqr8L63nzi-tzVVbqPZrzJ1UC68-F-te3AVM13FumKgOXz7qL27DixavkoM4wF7Bhp29hqfj9kT-DZz3O8bneKGTzB2ZIbwPpXcvNHGqaf6SX5j_QdrjILKchTs01pBmTjwEJb9t40cjNl9RKLyF74fDaX-UttUaUp1xH21poQtRippVLjMVq5mjwtmAbwSrNFWaadYrVM5V7pSqODKDOWd7plauNpzvwKbvnn0PhBtuy5IqZy33pqxqD4KKoies0bl_bxKgK7vIP5GUQ_6zmPEqk6gyiSqTQWXyOoEvwYCdgLq6xKS2Mpc_JkfyqBiMz8TPqRwksLdm4U7AL74Ech0lQFYml94X8YBFzex8uZAVntqKTOQJvItD4VaYIv8qFQkUweL37rcc9o_x6cNDBffh2Wg6PpWnx5OTj_DcN2Ex8-gTbDZXS7sLTxZmuRec5QZzpg_S
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BK1VcypsGaPEBcQtaP5I4R7SPtkBXK1FExcVy_JAqYLfqZqXy7_HY2dCteqgQtyjKRM6MZ_w5M_4G4G3schRwaM4a7XJhncsbw6rcSmpcYYVIdE1HX6rpmRyNkSbn4_osTOKH6H-4oWfEeI0OfmH9ppPHCq0QgTsmzoDkq_cBT26LgMqRR5_zWR-VJeWJOZyKnNXVjaqeW9-0sVRto9avsHRSL4P2fGp7cRsu3YS5cZ2aPPyfX_gIdju0Sj6k6fUY7rn5E9g56fLxT-Fs2PM9p-OcZOHJHMF9bLx7bojXbfub_MTqD9Ilg8hqHk_QOEvaBQkAlPxybZiL-PiaQOEZfJ2MT4dHederITeCh1hLS1PKSjas9sLWrGGeSu8iupGsNlQbZtig1AXXhde65sgL5r0b2Eb7xnL-HLbC8NweEG65qyqqvXNclKJuAgQqy4F01hThvs2Ars2iLhIlh7q2lQkqU6gyhSpTUWXqKoN30X69gL78gSVtVaG-TQ_VYTk6mcnvp2qUwcGGgXuBsPWSyHSUAVlbXAVPxPSKnrvFaqlqzNlKIYsMXqSZ8FeYIvsqlRmU0eB3HrcaD4_x6uW_Cr6Bndlooj4fTz-9ggfhCZbKjl7DVnu5cvtwf2lXB9FV_gAFGw54
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterization+of+nonalcoholic+fatty+liver+disease+unrelated+to+the+metabolic+syndrome&rft.jtitle=European+journal+of+clinical+investigation&rft.au=Yilmaz%2C+Yusuf&rft.au=Senates%2C+Ebubekir&rft.au=Ayyildiz%2C+Talat&rft.au=Colak%2C+Yasar&rft.date=2012-04-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0014-2972&rft.eissn=1365-2362&rft.volume=42&rft.issue=4&rft.spage=411&rft.epage=418&rft_id=info:doi/10.1111%2Fj.1365-2362.2011.02597.x&rft.externalDBID=10.1111%252Fj.1365-2362.2011.02597.x&rft.externalDocID=ECI2597
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2972&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2972&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2972&client=summon